Susan Murphy

About

Susan Murphy is a faculty member associated with the Statistical Reinforcement Learning Lab at Harvard University. Her contact information includes the Science Center at 400 Suite One Oxford Street, Cambridge, MA 02138-2901, with an administrative contact Jess Jackson. Her email is samurphy@fas.harvard.edu. The page lists her as a prominent figure in the lab, which focuses on statistical reinforcement learning, indicating her research interests lie in this area. The detailed biography, background, and key contributions are not explicitly provided on the page, which primarily serves as a member directory.

Research topics

• Medicine
• Internal medicine
• Cardiology
• Endocrinology

Selected publications

• Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT

  Circulation · 2022 · 81 citations

  BACKGROUND: The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients remain uncertain. METHODS: COVID-PACT (Prevention of Arteriovenous Thrombotic Events in Critically-ill COVID-19 Patients Trial) was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded end point adjudication in intensive care unit-level patients with COVID-19. Patients were randomly assigned to a strategy of full-dose anticoagula…

  DOI

• Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia

  New England Journal of Medicine · 2025-08-30 · 47 citations

  articleOpen access

  BACKGROUND: -acetylgalactosamine-conjugated antisense oligonucleotide that targets the messenger RNA of apolipoprotein C-III, which inhibits triglyceride clearance. METHODS: In this phase 3, international, double-blind, randomized, placebo-controlled trial, we enrolled patients with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter) and randomly assigned t…

  PublisherOA PDFDOI

• Estimating and presenting non-linear associations with restricted cubic splines

  International Journal of Epidemiology · 2025-06-11 · 42 citations

  articleOpen access

  Most of the regression models commonly used in epidemiology-including logistic regression and methods for time-to-event outcomes such as Cox regression-define the relationship between a set of covariates and the outcome of interest using linear functions, thus making implicit assumptions of linearity for continuous covariates. Categorizing continuous covariates, which represents a common option to address non-linearities, introduces additional assumptions and has recognized limitations in terms…

  PublisherOA PDFDOI

• Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

  New England Journal of Medicine · 2025-11-08 · 33 citations

  article

  BACKGROUND: Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population. METHODS: We conducted two double-blind, randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b). Patients with severe hypertriglyceridemia were assigned in a 1:1:1 ratio to receive olezarsen at a dose of 50 mg, olezarsen at…

  PublisherDOI

• Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

  Circulation · 2025-08-30 · 28 citations

  articleOpen access

  BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death o…

  PublisherOA PDFDOI

Recent grants

• NIH Grant U10CA030969

  NIH · $55.1M · 2003

Frequent coauthors

• Eugene Braunwald

  Harvard University

  1537 shared

• David A. Morrow

  Brigham and Women's Hospital

  1264 shared

• Marc S. Sabatine

  Harvard University

  1094 shared

• Elliott M. Antman

  Brigham and Women's Hospital

  1066 shared

• Robert P. Giugliano

  Brigham and Women's Hospital

  896 shared

• Christopher P. Cannon

  Harvard University

  774 shared

• Benjamin M. Scirica

  Brigham and Women's Hospital

  748 shared

• Carolyn H. McCabe

  707 shared

Labs

• Statistical Reinforcement Learning LabPI

Awards & honors

• MacArthur Fellowship (2013)
• Member of the National Academy of Medicine (2014)
• Member of the National Academy of Sciences of the US Nationa…

Similar researchers at Harvard University

• Donald B. Rubinh-151
• Giovanni Parmigianih-141
• Kosuke Imaih-67